{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:18:25Z","timestamp":1787026705630,"version":"build-2736575974"},"reference-count":264,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T00:00:00Z","timestamp":1681171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    Inflammatory bowel disease (IBD), which includes Crohn\u2019s disease (CD) and ulcerative colitis (UC), is a complex, immune-mediated, disorder which leads to several gastrointestinal and systemic manifestations determining a poor quality of life, disability, and other negative health outcomes. Our knowledge of this condition has greatly improved over the last few decades, and a comprehensive management should take into account both biological (i.e., disease-related, patient-related) and non-biological (i.e., socioeconomic, cultural, environmental, behavioral) factors which contribute to the disease phenotype. From this point of view, the so called 4P medicine framework, including personalization, prediction, prevention, and participation could be useful for tailoring\n                    <jats:italic>ad hoc<\/jats:italic>\n                    interventions in IBD patients. In this review, we discuss the cutting-edge issues regarding personalization in special settings (i.e., pregnancy, oncology, infectious diseases), patient participation (i.e., how to communicate, disability, tackling stigma and resilience, quality of care), disease prediction (i.e., faecal markers, response to treatments), and prevention (i.e., dysplasia through endoscopy, infections through vaccinations, and post-surgical recurrence). Finally, we provide an outlook discussing the unmet needs for implementing this conceptual framework in clinical practice.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2023.1031998","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T03:34:12Z","timestamp":1681184052000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Personalize, participate, predict, and prevent: 4Ps in inflammatory bowel disease"],"prefix":"10.3389","volume":"10","author":[{"given":"Marco Vincenzo","family":"Lenti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Lia","family":"Scribano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Biancone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachele","family":"Ciccocioppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Pastorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gionata","family":"Fiorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Savarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio Andrea","family":"Caprioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Ardizzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo Claudio","family":"Fantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Eugenio","family":"Tontini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambrogio","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca Matteo","family":"Sampietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo Carlo","family":"Sturniolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Monteleone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Vecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Daperno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"D\u2019Inc\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gino Roberto","family":"Corazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Di Sabatino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41572-020-0156-2","article-title":"Crohn's disease","volume":"6","author":"Roda","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","article-title":"Ulcerative colitis","volume":"6","author":"Kobayashi","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.mam.2018.10.003","article-title":"Intestinal fibrosis","volume":"65","author":"Lenti","year":"2019","journal-title":"Mol Asp Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s11739-019-02268-0","article-title":"Stigmatisation and resilience in inflammatory bowel disease","volume":"15","author":"Lenti","year":"2020","journal-title":"Intern Emerg Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017","volume":"5","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"651415","DOI":"10.3389\/fphar.2021.651415","article-title":"Novel and emerging therapies for inflammatory bowel disease","volume":"12","author":"Al-Bawardy","year":"2021","journal-title":"Front Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejim.2018.11.009","article-title":"Bringing complexity into clinical practice: an internistic approach","volume":"61","author":"Corazza","year":"2019","journal-title":"Eur J Intern Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/ecco-jcc\/jjab177","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: surgical treatment","volume":"16","author":"Spinelli","year":"2022","journal-title":"J Crohns Colitis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/ecco-jcc\/jjz187","article-title":"ECCO guidelines on therapeutics in Crohn's disease: surgical treatment","volume":"14","author":"Adamina","year":"2020","journal-title":"J Crohns Colitis"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn's disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohns Colitis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2217\/pme.13.57","article-title":"P4 medicine: how systems medicine will transform the healthcare sector and society","volume":"10","author":"Flores","year":"2013","journal-title":"Per Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1093\/ecco-jcc\/jjw052","article-title":"Perceptions and attitudes towards medication adherence during pregnancy in inflammatory bowel disease","volume":"10","author":"Gallinger","year":"2016","journal-title":"J Crohns Colitis"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/j.1365-2036.2011.04794.x","article-title":"European Crohn-colitis organisation (ECCO) study Group of Epidemiologic Committee (EpiCom). Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006","volume":"34","author":"Bortoli","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1053\/j.gastro.2018.12.022","article-title":"Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD parenthood project working group","volume":"156","author":"Mahadevan","year":"2019","journal-title":"Gastroenterology"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/ecco-jcc\/jju006","article-title":"European Crohn\u2019s and colitis organization. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease","volume":"9","author":"van der Woude","year":"2015","journal-title":"J Crohns Colitis"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1053\/j.gastro.2015.12.003","article-title":"The Toronto consensus statements for the Management of Inflammatory Bowel Disease in pregnancy","volume":"150","author":"Nguyen","year":"2016","journal-title":"Gastroenterology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.dld.2021.05.020","article-title":"Female reproductive health and inflammatory bowel disease: a practice-based review","volume":"54","author":"Armuzzi","year":"2022","journal-title":"Dig Liver Dis"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1136\/gutjnl-2021-325317","article-title":"Exposure to corticosteroids in pregnancy is associated with adverse perinatal outcomes among infants of mothers with inflammatory bowel disease: results from the PIANO registry","volume":"71","author":"Odufalu","year":"2021","journal-title":"Gut"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.cgh.2017.02.041","article-title":"Use of Thiopurines during conception and pregnancy is not associated with adverse pregnancy outcomes or health of infants at one year in a prospective study","volume":"15","author":"Kanis","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1053\/j.gastro.2020.11.038","article-title":"Pregnancy and neonatal outcomes after fetal exposure to biologics and Thiopurines among women with inflammatory bowel disease","volume":"160","author":"Mahadevan","year":"2021","journal-title":"Gastroenterology"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1002\/ibd.20858","article-title":"Cyclosporine treatment of steroid-refractory ulcerative colitis during pregnancy","volume":"15","author":"Branche","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.cgh.2020.09.021","article-title":"Biologics for inflammatory bowel disease and their safety in pregnancy: a systematic review and meta-analysis","volume":"20","author":"Nielsen","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1038\/s41395-018-0202-9","article-title":"Pregnancy outcomes reported during the 13-year TREAT registry: a descriptive report","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/ajg.2017.501","article-title":"Long-term safety of in utero exposure to anti-TNF\u03b1 drugs for the treatment of inflammatory bowel disease: results from the multicenter European TEDDY study","volume":"113","author":"Chaparro","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/ecco-jcc\/jjy142","article-title":"Outcome of pregnancies in female patients with inflammatory bowel diseases treated with Vedolizumab","volume":"13","author":"Moens","year":"2019","journal-title":"J Crohns Colitis"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.14309\/ajg.0000000000000186","article-title":"Exposure to Vedolizumab in IBD pregnant women appears of low risk for mother and neonate: a first prospective comparison study","volume":"114","author":"Bar-Gil Shitrit","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/apt.15539","article-title":"Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study","volume":"51","author":"Moens","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/apt.16192","article-title":"Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study","volume":"53","author":"Wils","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"i491","DOI":"10.1093\/ecco-jcc\/jjab232.672","article-title":"Safety of ustekinumab in pregnant patients with inflammatory bowel disease and in their offspring: results from the DUMBO registry of GETECCU","volume":"16","author":"Chaparro","year":"2022","journal-title":"J Crohns Colitis"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s40264-016-0431-z","article-title":"Pregnancy outcomes in the Tofacitinib safety databases for rheumatoid arthritis and psoriasis","volume":"39","author":"Clowse","year":"2016","journal-title":"Drug Saf"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1093\/ibd\/izy160","article-title":"Outcomes of pregnancies with maternal\/paternal exposure in the Tofacitinib safety databases for ulcerative colitis","volume":"24","author":"Mahadevan","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1056\/NEJMra1403718","article-title":"Cancers complicating inflammatory bowel disease","volume":"372","author":"Beaugerie","year":"2015","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/ecco-jcc\/jjv141","article-title":"European evidence-based consensus: inflammatory bowel disease and malignancies","volume":"9","author":"Annese","year":"2015","journal-title":"J Crohns Colitis"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1136\/gutjnl-2013-305763","article-title":"Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer","volume":"63","author":"Beaugerie","year":"2014","journal-title":"Gut"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/j.gastro.2016.03.037","article-title":"Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis","volume":"151","author":"Shelton","year":"2016","journal-title":"Gastroenterology"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1136\/ard.2008.093690","article-title":"Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1136\/gut.2005.075937","article-title":"Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study","volume":"55","author":"Biancone","year":"2006","journal-title":"Gut"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/ajg.2013.441","article-title":"Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT\u2122 registry","volume":"109","author":"Lichtenstein","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.cgh.2016.04.039","article-title":"Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis","volume":"14","author":"Bonovas","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1001\/jama.2014.5613","article-title":"Association between tumor necrosis factor-\u03b1 antagonists and risk of cancer in patients with inflammatory bowel disease","volume":"311","author":"Nyboe Andersen","year":"2014","journal-title":"JAMA"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/apt.12624","article-title":"Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-\u03b1 therapy in inflammatory bowel disease","volume":"39","author":"Williams","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.cgh.2013.04.033","article-title":"Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis","volume":"12","author":"Singh","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cgh.2010.09.016","article-title":"A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease","volume":"9","author":"Kotlyar","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.cgh.2015.07.037","article-title":"Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents","volume":"14","author":"Axelrad","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1097\/MIB.0000000000000741","article-title":"Risk of incident cancer in inflammatory bowel disease patients starting anti-TNF therapy while having recent malignancy","volume":"22","author":"Poullenot","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/apt.15538","article-title":"Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data","volume":"51","author":"Card","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1093\/ibd\/izaa236","article-title":"Safety of Ustekinumab in inflammatory bowel disease: pooled safety analysis of results from phase 2\/3 studies","volume":"27","author":"Sandborn","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.cgh.2020.10.007","article-title":"Vedolizumab or tumor necrosis factor antagonist use and risk of new or recurrent cancer in patients with inflammatory bowel disease with prior malignancy: a retrospective cohort study","volume":"20","author":"Vedamurthy","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/ibd\/izac035","article-title":"Ustekinumab and Vedolizumab are not associated with subsequent cancer in IBD patients with prior malignancy","volume":"28","author":"Hong","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/apt.16712","article-title":"Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE open, an open-label, long-term extension study with up to 7.0 years of treatment","volume":"55","author":"Sandborn","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/j.1572-0241.1999.01013.x","article-title":"Cytomegalovirus infection in patients with inflammatory bowel disease","volume":"94","author":"Vega","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1111\/j.1572-0241.1999.01148.x","article-title":"Epstein-Barr virus infection of the colon with inflammatory bowel disease","volume":"94","author":"Yanai","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/s1369-5274(02)00334-x","article-title":"Human cytomegalovirus persistence and latency in endothelial cells and macrophages","volume":"5","author":"Jarvis","year":"2002","journal-title":"Curr Opin Microbiol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jcv.2007.11.014","article-title":"Human cytomegalovirus: latency and reactivation in the myeloid lineage","volume":"41","author":"Sinclair","year":"2008","journal-title":"J Clin Virol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.coviro.2013.04.005","article-title":"The pathogenesis of Epstein-Barr virus persistent infection","volume":"3","author":"Thorley-Lawson","year":"2013","journal-title":"Curr Opin Virol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/j.1365-2796.2010.02220.x","article-title":"Modulation of host innate and adaptive immune defenses by cytomegalovirus: timing is everything","volume":"267","author":"Loewendorf","year":"2010","journal-title":"J Intern Med"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/rmv.1780","article-title":"Switching of EBV cycles between latent and lytic states","volume":"24","author":"Murata","year":"2014","journal-title":"Rev Med Virol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/jmv.22258","article-title":"Longitudinal analysis of frequency and reactivity of Epstein-Barr virus-specific T lymphocytes and their association with intermittent viral reactivation","volume":"84","author":"Vogl","year":"2012","journal-title":"J Med Virol"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/apt.13124","article-title":"Review article: cytomegalovirus and inflammatory bowel disease","volume":"41","author":"Sager","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1007\/s10620-012-2116-5","article-title":"Epstein-Barr virus infection is common in inflamed gastrointestinal mucosa","volume":"57","author":"Ryan","year":"2012","journal-title":"Dig Dis Sci"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.3748\/wjg.v21.i6.1915","article-title":"Human cytomegalovirus and Epstein-Barr virus infection in inflammatory bowel disease: need for mucosal viral load measurement","volume":"21","author":"Ciccocioppo","year":"2015","journal-title":"World J Gastroenterol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/infdis\/162.1.39","article-title":"The effects of a promoter of cell differentiation and selected hormones on human cytomegalovirus infection using an in vitro cell system","volume":"162","author":"Forbes","year":"1990","journal-title":"J Infect Dis"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/01.meg.0000108345.41221.c2","article-title":"Infliximab: mechanism of action beyond TNF-alpha neutralization in inflammatory bowel disease","volume":"16","author":"Kirman","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1084\/jem.20050882","article-title":"Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects","volume":"202","author":"Sylwester","year":"2005","journal-title":"J Exp Med"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the Management of Cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/ajt.12004","article-title":"Epstein-Barr virus infection and posttransplant lymphoproliferative disorder","volume":"13","author":"Green","year":"2013","journal-title":"Am J Transplant"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1182\/blood.2019000924","article-title":"Virus-specific T-cell therapies for patients with primary immune deficiency","volume":"135","author":"Keller","year":"2020","journal-title":"Blood"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10238-021-00702-2","article-title":"Human cytomegalovirus and Epstein-Barr virus specific immunity in patients with ulcerative colitis","volume":"21","author":"Ciccocioppo","year":"2021","journal-title":"Clin Exp Med"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1053\/gast.2002.30328","article-title":"Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine","volume":"122","author":"Dayharsh","year":"2002","journal-title":"Gastroenterology"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000253862","article-title":"Patients' preferences regarding shared decision-making in the treatment of inflammatory bowel disease: results from a patient-empowerment study","volume":"81","author":"Baars","year":"2010","journal-title":"Digestion"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.pec.2012.02.010","article-title":"Shared decision making and other variables as correlates of satisfaction with health care decisions in a United States national survey","volume":"88","author":"Glass","year":"2012","journal-title":"Patient Educ Couns"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1097\/MLR.0b013e31819a5acc","article-title":"Physician communication and patient adherence to treatment: a meta-analysis","volume":"47","author":"Zolnierek","year":"2009","journal-title":"Med Care"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.crohns.2013.12.023","article-title":"Health care and patients' education in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom study","volume":"8","author":"Burisch","year":"2014","journal-title":"J Crohns Colitis"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"509","DOI":"10.5217\/ir.2018.00074","article-title":"Optimizing the multidimensional aspects of the patient-physician relationship in the management of inflammatory bowel disease","volume":"16","author":"Chew","year":"2018","journal-title":"Intest Res"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1097\/00006842-199111000-00010","article-title":"The rating form of IBD patient concerns: a new measure of health status","volume":"53","author":"Drossman","year":"1991","journal-title":"Psychosom Med"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/ibd.21363","article-title":"Information needs and preferences of recently diagnosed patients with inflammatory bowel disease","volume":"17","author":"Bernstein","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1093\/ibd\/izaa257","article-title":"Ulcerative colitis narrative global survey findings: communication gaps and agreements between patients and physicians","volume":"27","author":"Rubin","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1093\/ibd\/izac025","article-title":"Self-reported failure to address sexual function in patients with inflammatory bowel disease by gastroenterologists: barriers and areas for improvement","volume":"28","author":"Christensen","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1136\/flgastro-2013-100400","article-title":"Perspectives and attitudes of young patients with inflammatory bowel disease: symptoms, burden of disease and communication with their healthcare professionals","volume":"5","author":"Alexakis","year":"2014","journal-title":"Frontline Gastroenterol"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.pec.2020.01.011","article-title":"Talking about Dr. Google: communication strategies used by nurse practitioners and patients with inflammatory bowel disease in the Netherlands to discuss online health information","volume":"103","author":"Linn","year":"2020","journal-title":"Patient Educ Couns"},{"key":"ref82","author":"Fischhoff","year":"2011"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.dld.2022.01.125","article-title":"Faecal incontinence in inflammatory bowel disease: the Nancy experience","volume":"54","author":"Kurt","year":"2022","journal-title":"Dig Liver Dis"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41598-020-57460-6","article-title":"Sleep disturbance in inflammatory bowel disease: prevalence and risk factors \u2013 a cross-sectional study","volume":"10","author":"Marinelli","year":"2020","journal-title":"Sci Rep"},{"key":"ref85","year":"1976"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1111\/apt.16353","article-title":"Determinants of IBD-related disability: a cross-sectional survey from the GETAID","volume":"53","author":"Tannoury","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1136\/gutjnl-2011-300049","article-title":"Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health","volume":"61","author":"Peyrin-Biroulet","year":"2012","journal-title":"Gut"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/MIB.0000000000001033","article-title":"Development of the IBD disk: a visual self-administered tool for assessing disability in inflammatory bowel diseases","volume":"23","author":"Ghosh","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"5354320","DOI":"10.1155\/2019\/5354320","article-title":"Influencing disability and quality of life during treatment: a cross-sectional study on IBD patients","volume":"2019","author":"Marinelli","year":"2019","journal-title":"Gastroenterol Res Pract"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1093\/ibd\/izz102","article-title":"Health care indicators of moderate to severe IBD and subsequent IBD-related disability: a longitudinal study","volume":"25","author":"Shafer","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"e761","DOI":"10.1016\/j.cgh.2021.05.033","article-title":"Ileal pouch anal anastomosis for the Management of Ulcerative Colitis is Associated with Significant Disability","volume":"20","author":"Kayal","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1159\/000506702","article-title":"Overcoming workplace disability in IBD patients: an observational study","volume":"5","author":"Paulides","year":"2020","journal-title":"Inflamm Intest Dis"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/2050640615577532","article-title":"IBD-related work disability in the community: prevalence, severity and predictive factors. A cross-sectional study","volume":"3","author":"Ramos","year":"2015","journal-title":"United Eur Gastroenterol J"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"165","DOI":"10.26355\/eurrev_202101_24382","article-title":"Inflammatory bowel diseases and work disability: a systematic review of predictive factors","volume":"25","author":"Leso","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1007\/s10620-020-06647-y","article-title":"Impaired quality of working life in inflammatory bowel disease patients","volume":"66","author":"van Gennep","year":"2021","journal-title":"Dig Dis Sci"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/ecco-jcc\/jjaa238","article-title":"Women's earnings are more affected by inflammatory bowel disease than Men's: a register-based Swedish cohort study","volume":"15","author":"Everhov","year":"2021","journal-title":"J Crohns Colitis"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1177\/1756283X17732720","article-title":"Preventing disability in inflammatory bowel disease","volume":"10","author":"Allen","year":"2017","journal-title":"Ther Adv Gastroenterol"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"6647","DOI":"10.3748\/wjg.v27.i39.6647","article-title":"Validation of the Italian translation of the perceived stigma scale and resilience assessment in inflammatory bowel disease patients","volume":"27","author":"Cococcia","year":"2021","journal-title":"World J Gastroenterol"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/CEG.S83533","article-title":"A systematic review of disease-related stigmatization in patients living with inflammatory bowel disease","volume":"9","author":"Taft","year":"2016","journal-title":"Clin Exp Gastroenterol"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/ibd.20864","article-title":"Impact of perceived stigma on inflammatory bowel disease patient outcomes","volume":"15","author":"Taft","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1146\/annurev.soc.27.1.363","article-title":"Conceptualizing stigma","volume":"27","author":"Link","year":"2001","journal-title":"Annu Rev Sociol"},{"key":"ref102","first-page":"16","article-title":"Understanding the impact of stigma on people with mental illness","volume":"1","author":"Corrigan","year":"2002","journal-title":"World Psychiatry"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1097\/01.aids.0000327438.13291.62","article-title":"Stigma in the HIV\/AIDS epidemic: a review of the literature and recommendations for the way forward","volume":"22","author":"Mahajan","year":"2008","journal-title":"AIDS"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2217\/14796694.4.5.717","article-title":"Stigma in cancer patients whose behavior may have contributed to their disease","volume":"4","author":"Lebel","year":"2008","journal-title":"Future Oncol"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/13548500902865956","article-title":"Development and initial validation of a measure of perceived stigma in irritable bowel syndrome","volume":"14","author":"Jones","year":"2009","journal-title":"Psychol Health Med"},{"key":"ref106","year":""},{"key":"ref107","doi-asserted-by":"publisher","first-page":"1024928","DOI":"10.4172\/2324-005.1000176","article-title":"Resilience in chronic diseases: a systematic review","volume":"2","author":"Cal","year":"2015","journal-title":"Cogent Psychol"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/978-3-030-32811-5_117-1","article-title":"Resilience: a perspective from the chronic disease in the adult population","volume":"9","author":"Quiceno","year":"2011","journal-title":"Pensam Psicol"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"e38562","DOI":"10.5812\/ircmj.38562","article-title":"Resilience of patients with chronic physical diseases: a systematic review and meta-analysis","volume":"18","author":"Ghanei Gheshlagh","year":"2016","journal-title":"Iran Red Crescent Med J"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/da.10113","article-title":"Development of a new resilience scale: the Connor-Davidson resilience scale (CD-RISC)","volume":"18","author":"Connor","year":"2003","journal-title":"Depress Anxiety"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12888-014-0227-6","article-title":"Building resilience for future adversity: a systematic review of interventions in non-clinical samples of adults","volume":"14","author":"Macedo","year":"2014","journal-title":"BMC Psychiatry"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/iwj.13076","article-title":"Depression and resilience in ulcerative colitis and Crohn's disease patients with ostomy","volume":"16","author":"Hwang","year":"2019","journal-title":"Int Wound J"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/ueg2.12122","article-title":"The new frontier: certifying quality standards in the inflammatory bowel disease care","volume":"9","author":"Fiorino","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/ecco-jcc\/jjab052","article-title":"ECCO guidelines on the prevention, diagnosis, and Management of Infections in inflammatory bowel disease","volume":"15","author":"Kucharzik","year":"2021","journal-title":"J Crohns Colitis"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications","volume":"13","author":"Maaser","year":"2019","journal-title":"J Crohns Colitis"},{"key":"ref116","first-page":"109","article-title":"The standard of care: legal history and definitions: the bad and good news","volume":"12","author":"Moffett","year":"2011","journal-title":"West J Emerg Med"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/ecco-jcc\/jjy140","article-title":"'Quality of Care' standards in inflammatory bowel disease: a systematic review","volume":"13","author":"Fiorino","year":"2019","journal-title":"J Crohns Colitis"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1093\/ecco-jcc\/jjaa023","article-title":"Quality of care standards in inflammatory bowel diseases: a European Crohn's and colitis organisation [ECCO] position paper","volume":"14","author":"Fiorino","year":"2020","journal-title":"J Crohns Colitis"},{"key":"ref119","year":"2021"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1056\/NEJMra0804647","article-title":"Inflammatory bowel disease","volume":"361","author":"Abraham","year":"2009","journal-title":"N Engl J Med"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","article-title":"Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial","volume":"142","author":"Rutgeerts","year":"2012","journal-title":"Gastroenterology"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.gie.2005.08.011","article-title":"Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease","volume":"63","author":"Rutgeerts","year":"2006","journal-title":"Gastrointest Endosc"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/apt.13475","article-title":"Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease","volume":"43","author":"Shah","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1177\/003693308302800106","article-title":"C-reactive protein as a predictor of relapse in asymptomatic patients with Crohn's disease","volume":"28","author":"Andr\u00e9","year":"1983","journal-title":"Scott Med J"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.gtc.2012.01.007","article-title":"Fecal markers: calprotectin and lactoferrin","volume":"41","author":"Abraham","year":"2012","journal-title":"Gastroenterol Clin N Am"},{"key":"ref126","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1097\/MIB.0000000000000057","article-title":"Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity","volume":"20","author":"Lin","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"ref127","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/ecco-jcc\/jjz023","article-title":"Faecal calprotectin is a very reliable tool to predict and monitor the risk of relapse after therapeutic De-escalation in patients with inflammatory bowel diseases","volume":"13","author":"Buisson","year":"2019","journal-title":"J Crohns Colitis"},{"key":"ref128","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/MCG.0000000000000774","article-title":"Accuracy of consecutive fecal calprotectin measurements to predict relapse in inflammatory bowel disease patients under maintenance with anti-TNF therapy: a prospective longitudinal cohort study","volume":"52","author":"Ferreiro-Iglesias","year":"2018","journal-title":"J Clin Gastroenterol"},{"key":"ref129","doi-asserted-by":"publisher","first-page":"1450970","DOI":"10.1155\/2017\/1450970","article-title":"Comparison of fecal calprotectin methods for predicting relapse of pediatric inflammatory bowel disease","volume":"2017","author":"Kittanakom","year":"2017","journal-title":"Can J Gastroenterol Hepatol"},{"key":"ref130","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/apt.13950","article-title":"Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission","volume":"45","author":"Diederen","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/MIB.0000000000000986","article-title":"Development and internal validation of a model using fecal calprotectin in combination with infliximab trough levels to predict clinical relapse in Crohn's disease","volume":"23","author":"Roblin","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"ref132","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.crohns.2014.01.029","article-title":"A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn's disease","volume":"8","author":"Naismith","year":"2014","journal-title":"J Crohns Colitis"},{"key":"ref133","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/j.1365-2036.2011.04743.x","article-title":"Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study","volume":"34","author":"Laharie","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"ref134","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1111\/j.1572-0241.2008.01870.x","article-title":"Can calprotectin predict relapse risk in inflammatory bowel disease?","volume":"103","author":"D'Inc\u00e0","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"ref135","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/gut.2004.043406","article-title":"Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease","volume":"54","author":"Costa","year":"2005","journal-title":"Gut"},{"key":"ref136","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1053\/gast.2000.8523","article-title":"Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease","volume":"119","author":"Tibble","year":"2000","journal-title":"Gastroenterology"},{"key":"ref137","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1002\/ibd.22861","article-title":"Faecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies","volume":"18","author":"Mao","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"ref138","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1053\/j.gastro.2015.01.026","article-title":"Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery","volume":"148","author":"Wright","year":"2015","journal-title":"Gastroenterology"},{"key":"ref139","doi-asserted-by":"publisher","first-page":"1756284818785571","DOI":"10.1177\/1756284818785571","article-title":"Fecal calprotectin for detection of postoperative endoscopic recurrence in Crohn's disease: systematic review and meta-analysis","volume":"11","author":"Tham","year":"2018","journal-title":"Ther Adv Gastroenterol"},{"key":"ref140","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1053\/j.gastro.2021.04.063","article-title":"Approach to the management of recently diagnosed inflammatory bowel disease patients: a user's guide for adult and pediatric gastroenterologists","volume":"161","author":"Agrawal","year":"2021","journal-title":"Gastroenterology"},{"key":"ref141","doi-asserted-by":"publisher","first-page":"CD000545","DOI":"10.1002\/14651858.CD000545.pub5","article-title":"Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease","volume":"10","author":"Chande","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"ref142","doi-asserted-by":"publisher","first-page":"CD000067","DOI":"10.1002\/14651858.CD000067.pub3","article-title":"Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease","volume":"2016","author":"Chande","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"ref143","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/gut.2005.068809","article-title":"Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis","volume":"55","author":"Ardizzone","year":"2006","journal-title":"Gut"},{"key":"ref144","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.3390\/jcm11092302","article-title":"An update on current Pharmacotherapeutic options for the treatment of ulcerative colitis","volume":"11","author":"Ferretti","year":"2022","journal-title":"J Clin Med"},{"key":"ref145","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1053\/j.gastro.2018.08.043","article-title":"Evolving considerations for Thiopurine therapy for inflammatory bowel diseases-A clinical practice update: commentary","volume":"156","author":"Hanauer","year":"2019","journal-title":"Gastroenterology"},{"key":"ref146","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/ibd.21221","article-title":"Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts","volume":"16","author":"Jharap","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"ref147","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3389\/fmed.2019.00279","article-title":"Can we predict the toxicity and response to thiopurines in iunfalmmatory bowel disease?","volume":"6","author":"Luber","year":"2019","journal-title":"Front Med"},{"key":"ref148","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1097\/MIB.0b013e318281f28f","article-title":"Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients","volume":"19","author":"Chaparro","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"ref149","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/ajg.2011.60","article-title":"Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review","volume":"106","author":"Billioud","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"ref150","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/MIB.0000000000000202","article-title":"Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse","volume":"21","author":"Papamichael","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"ref151","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"ref152","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"ref153","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"ref154","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"ref155","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1093\/ecco-jcc\/jjz195","article-title":"Predictors of primary response to biologic treatment [anti-TNF, Vedolizumab, and Ustekinumab] in patients with inflammatory bowel disease: from basic science to clinical practice","volume":"14","author":"Gisbert","year":"2020","journal-title":"J Crohns Colitis"},{"key":"ref156","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/ecco-jcc\/jju018","article-title":"Smoking and early infliximab response in Crohn\u2019s disease: a meta-analysis","volume":"9","author":"Inamdar","year":"2015","journal-title":"J Crohns Colitis"},{"key":"ref157","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1155\/2009\/431349","article-title":"Does smoking reduce infliximab's effectiveness against Crohn's disease?","volume":"23","author":"Narula","year":"2009","journal-title":"Can J Gastroenterol"},{"key":"ref158","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000492626","article-title":"Fecal calprotectin pretreatment and induction infliximab levels for prediction of primary nonresponse to infliximab therapy in Crohn's disease","volume":"37","author":"Beltr\u00e1n","year":"2019","journal-title":"Dig Dis"},{"key":"ref159","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"ref160","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/ajg.2008.119","article-title":"Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis","volume":"104","author":"Ho","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"ref161","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.cgh.2011.02.008","article-title":"Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease","volume":"9","author":"J\u00fcrgens","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref162","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1080\/gas.37.7.818.824","article-title":"A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with \u2212308 TNF gene polymorphism","volume":"37","author":"Louis","year":"2002","journal-title":"Scand J Gastroenterol"},{"key":"ref163","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/apt.13893","article-title":"Swedish Organization for the Study of inflammatory bowel diseases (SOIBD). Long-term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients","volume":"45","author":"Angelison","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"ref164","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/ecco-jcc\/jjx146","article-title":"Exploration of predictive biomarkers of early infliximab response in acute severe colitis: a prospective pilot study","volume":"12","author":"Beswick","year":"2018","journal-title":"J Crohns Colitis"},{"key":"ref165","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.3109\/00365521.2015.1031167","article-title":"Global mucosal and serum cytokine profile in patients with ulcerative colitis undergoing anti-TNF therapy","volume":"50","author":"Dahl\u00e9n","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"ref166","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/j.1365-2036.2004.01871.x","article-title":"Association between polymorphism in IgG fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease","volume":"19","author":"Louis","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"ref167","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1053\/j.gastro.2019.09.041","article-title":"PANTS consortium. HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn's disease","volume":"158","author":"Sazonovs","year":"2020","journal-title":"Gastroenterology"},{"key":"ref168","first-page":"1","article-title":"A SPECIAL MEETING REVIEW EDITION: Highlights in anti-tumor necrosis factor monitoring and antibody monitoring from the 2014 DDW meeting: digestive disease week 2014 may 3-6, 2014 \u2022 Chicago, Illinois","volume":"10","year":"2014","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"ref169","doi-asserted-by":"publisher","first-page":"jjw203","DOI":"10.1093\/ecco-jcc\/jjw203","article-title":"Prediction of short- and medium-term efficacy of biosimilar infliximab therapy. Do trough levels and antidrug antibody levels or clinical and biochemical markers play the more important role?","volume":"11","author":"Gonczi","year":"2017","journal-title":"J Crohns Colitis"},{"key":"ref170","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1007\/s10620-020-06645-0","article-title":"Infliximab trough levels are not predictive of relapse in patients with IBD in endoscopic remission: a multicenter cohort study","volume":"66","author":"Borren","year":"2021","journal-title":"Dig Dis Sci"},{"key":"ref171","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1136\/gutjnl-2017-315494","article-title":"Cell-centred meta-analysis reveals baseline predictors of anti-TNF\u03b1 non-response in biopsy and blood of patients with IBD","volume":"68","author":"Gaujoux","year":"2019","journal-title":"Gut"},{"key":"ref172","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.ebiom.2019.01.027","article-title":"Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease","volume":"40","author":"Verstockt","year":"2019","journal-title":"EBioMedicine"},{"key":"ref173","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/apt.15870","article-title":"Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab","volume":"52","author":"Bertani","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"ref174","doi-asserted-by":"publisher","first-page":"otz026","DOI":"10.1093\/crocol\/otz026","article-title":"Elevated pretreatment plasma Oncostatin M is associated with poor biochemical response to infliximab","volume":"1","author":"Minar","year":"2019","journal-title":"Crohns Colitis"},{"key":"ref175","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nm.3462","article-title":"In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease","volume":"20","author":"Atreya","year":"2014","journal-title":"Nat Med"},{"key":"ref176","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.gie.2017.01.012","article-title":"Molecular imaging of mucosal alpha4beta7 integrin expression with the fluorescent anti-adhesion antibody vedolizumab in Crohn's disease","volume":"86","author":"Rath","year":"2017","journal-title":"Gastrointest Endosc"},{"key":"ref177","doi-asserted-by":"publisher","first-page":"izac233","DOI":"10.1093\/ibd\/izac233","article-title":"Computer-aided imaging analysis of probe-based confocal laser Endomicroscopy with molecular labeling and gene expression identifies markers of response to biological therapy in IBD patients: the Endo-omics study","author":"Iacucci","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"ref178","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.chom.2017.04.010","article-title":"Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases","volume":"21","author":"Ananthakrishnan","year":"2017","journal-title":"Cell Host Microbe"},{"key":"ref179","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.gie.2021.12.048","article-title":"Real-time use of artificial intelligence at colonoscopy predicts relapse in ulcerative colitis: predicting with \"intelligence\"","volume":"95","author":"Limdi","year":"2022","journal-title":"Gastrointest Endosc"},{"key":"ref180","doi-asserted-by":"publisher","first-page":"17562848211017730","DOI":"10.1177\/17562848211017730","article-title":"Artificial intelligence in gastrointestinal endoscopy for inflammatory bowel disease: a systematic review and new horizons","volume":"14","author":"Tontini","year":"2021","journal-title":"Ther Adv Gastroenterol"},{"key":"ref181","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1053\/j.gastro.2020.12.024","article-title":"An international multicenter real-life prospective study of electronic Chromoendoscopy score PICaSSO in ulcerative colitis","volume":"160","author":"Iacucci","year":"2021","journal-title":"Gastroenterology"},{"key":"ref182","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/ueg2.12185","article-title":"PICaSSO virtual electronic chromendoscopy accurately reflects combined endoscopic and histological assessment for prediction of clinical outcomes in ulcerative colitis. United European","volume":"10","author":"Nardone","year":"2022","journal-title":"Gastroenterol J"},{"key":"ref183","doi-asserted-by":"publisher","first-page":"i017","DOI":"10.1093\/ecco-jcc\/jjab232.015","article-title":"OP16 the first virtual chromoendoscopy artificial intelligence system to detect endoscopic and histologic remission in ulcerative colitis","volume":"16","author":"Iacucci","year":"2022","journal-title":"J Crohn's Colitis"},{"key":"ref184","doi-asserted-by":"publisher","first-page":"i015","DOI":"10.1093\/ecco-jcc\/jjab232.014","article-title":"OP15 A new simplified histology artificial intelligence system for accurate assessment of remission in ulcerative colitis","volume":"16","author":"Villanacci","year":"2022","journal-title":"J Crohn's Colitis"},{"key":"ref185","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1136\/gutjnl-2019-320056","article-title":"Automatic, computer-aided determination of endoscopic and histological inflammation in patients with mild to moderate ulcerative colitis based on red density","volume":"69","author":"Bossuyt","year":"2020","journal-title":"Gut"},{"key":"ref186","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1053\/j.gastro.2020.09.053","article-title":"Computer-aided diagnosis with monochromatic light endoscopy for scoring histologic remission in ulcerative colitis","volume":"160","author":"Bossuyt","year":"2021","journal-title":"Gastroenterology"},{"key":"ref187","doi-asserted-by":"publisher","first-page":"e193963","DOI":"10.1001\/jamanetworkopen.2019.3963","article-title":"Performance of a deep learning model vs human reviewers in grading endoscopic disease severity of patients with ulcerative colitis","volume":"2","author":"Stidham","year":"2019","journal-title":"JAMA Netw Open"},{"key":"ref188","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1053\/j.gastro.2020.10.024","article-title":"Central Reading of ulcerative colitis clinical trial videos using neural networks","volume":"160","author":"Gottlieb","year":"2021","journal-title":"Gastroenterology"},{"key":"ref189","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1109\/EMBC.2019.8856625","article-title":"Automated detection of non-informative frames for colonoscopy through a combination of deep learning and feature extraction","volume":"2019","author":"Yao","year":"2019","journal-title":"Annu Int Conf IEEE Eng Med Biol Soc"},{"key":"ref190","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1053\/j.gastro.2021.01.210","article-title":"Deep neural network accurately predicts prognosis of ulcerative colitis using endoscopic images","volume":"160","author":"Takenaka","year":"2021","journal-title":"Gastroenterology"},{"key":"ref191","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/apt.15778","article-title":"Systematic review with meta-analysis: IBD-associated colonic dysplasia prognosis in the videoendoscopic era (1990 to present)","volume":"52","author":"Kabir","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"ref192","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S2468-1253(19)30194-3","article-title":"Improving the quality of surveillance colonoscopy in inflammatory bowel disease","volume":"4","author":"Iacucci","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref193","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1111\/den.14335","article-title":"Use of advanced endoscopic technology for optical characterization of neoplasia in patients with ulcerative colitis: a systematic review","volume":"34","author":"Maeda","year":"2022","journal-title":"Dig Endosc"},{"key":"ref194","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1053\/j.gastro.2021.05.063","article-title":"AGA clinical practice update on endoscopic surveillance and Management of Colorectal Dysplasia in inflammatory bowel diseases: expert review","volume":"161","author":"Murthy","year":"2021","journal-title":"Gastroenterology"},{"key":"ref195","doi-asserted-by":"publisher","first-page":"E273","DOI":"10.1055\/a-1261-2944","article-title":"Can artificial intelligence help to detect dysplasia in patients with ulcerative colitis?","volume":"53","author":"Maeda","year":"2021","journal-title":"Endoscopy"},{"key":"ref196","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"8","author":"Rahier","year":"2014","journal-title":"J Crohns Colitis"},{"key":"ref197","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jinf.2017.02.009","article-title":"Diagnostic and vaccine strategies to prevent infections in patients with inflammatory bowel disease","volume":"74","author":"Mazzola","year":"2017","journal-title":"J Infect"},{"key":"ref198","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2013","journal-title":"Clin Infect Dis"},{"key":"ref199","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.cgh.2010.09.026","article-title":"Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease","volume":"9","author":"Cottone","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref200","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","article-title":"Risk factors for opportunistic infections in patients with inflammatory bowel disease","volume":"134","author":"Toruner","year":"2008","journal-title":"Gastroenterology"},{"key":"ref201","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT\u2122 registry","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"ref202","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn's disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"ref203","doi-asserted-by":"publisher","first-page":"CD007572","DOI":"10.1002\/14651858.CD007572.pub3","article-title":"Anti-IL-12\/23p40 antibodies for induction of remission in Crohn's disease","volume":"2016","author":"MacDonald","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"ref204","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1093\/ibd\/izy131","article-title":"Herpes zoster infection in patients with ulcerative colitis receiving Tofacitinib","volume":"24","author":"Winthrop","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"ref205","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cgh.2020.10.027","article-title":"Herpes zoster and vaccination strategies in inflammatory bowel diseases: a practical guide","volume":"20","author":"Guillo","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref206","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B virus infection","volume":"57","year":"2012","journal-title":"J Hepatol"},{"key":"ref207","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.cgh.2007.04.007","article-title":"Risk for active tuberculosis in inflammatory bowel disease patients","volume":"5","author":"Aberra","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref208","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"ref209","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1002\/ibd.22889","article-title":"Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease","volume":"18","author":"Sokol","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"ref210","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/j.1572-0241.2007.01582.x","article-title":"Higher incidence of abnormal pap smears in women with inflammatory bowel disease","volume":"103","author":"Kane","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"ref211","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1086\/648963","article-title":"Epidemiological profile of meningococcal disease in the United States","volume":"50","author":"Harrison","year":"2010","journal-title":"Clin Infect Dis"},{"key":"ref212","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the advisory committee on immunization practices (ACIP)","volume":"22","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"ref213","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.rgmx.2020.05.001","article-title":"Aspects of inflammatory bowel disease during the COVID-19 pandemic and general considerations","volume":"85","author":"De Le\u00f3n-Rend\u00f3n","year":"2020","journal-title":"Rev Gastroenterol Mex (Engl Ed)"},{"key":"ref214","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/gutjnl-2020-324000","article-title":"SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting","volume":"70","author":"Siegel","year":"2021","journal-title":"Gut"},{"key":"ref215","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.dld.2021.05.015","article-title":"Vaccinations in patients with inflammatory bowel disease","volume":"53","author":"Macaluso","year":"2021","journal-title":"Dig Liver Dis"},{"key":"ref216","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1093\/ecco-jcc\/jjaa107","article-title":"Segmental colectomy for ulcerative colitis: is there a place in selected patients without active colitis? An international multicentric retrospective study in 72 patients","volume":"14","author":"Frontali","year":"2020","journal-title":"J Crohns Colitis"},{"key":"ref217","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.crohns.2014.08.012","article-title":"European evidence based consensus on surgery for ulcerative colitis","volume":"9","author":"\u00d8resland","year":"2015","journal-title":"J Crohns Colitis"},{"key":"ref218","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10151-020-02175-z","article-title":"Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): ulcerative colitis","volume":"24","author":"Pellino","year":"2020","journal-title":"Tech Coloproctol"},{"key":"ref219","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/ecco-jcc\/jjw209","article-title":"Restorative Proctocolectomy in elderly IBD patients: a multicentre comparative study on safety and efficacy","volume":"11","author":"Colombo","year":"2017","journal-title":"J Crohns Colitis"},{"key":"ref220","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.3390\/jcm9103382","article-title":"Sequential approach for a critical-view COlectomy (SACCO): a laparoscopic technique to reduce operative time and complications in IBD acute severe colitis","volume":"9","author":"Sampietro","year":"2020","journal-title":"J Clin Med"},{"key":"ref221","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1111\/codi.15928","article-title":"Acute severe ulcerative colitis: how to reduce operating time under 150 min for emergency laparoscopic colectomy \u2013 a video vignette","volume":"23","author":"Frontali","year":"2021","journal-title":"Color Dis"},{"key":"ref222","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1097\/SLA.0b013e318250caa9","article-title":"Significantly increased pregnancy rates after laparoscopic restorative proctocolectomy: a cross-sectional study","volume":"256","author":"Bartels","year":"2012","journal-title":"Ann Surg"},{"key":"ref223","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjx061","article-title":"ECCO-ESCP consensus on surgery for Crohn's disease","volume":"12","author":"Bemelman","year":"2018","journal-title":"J Crohns Colitis"},{"key":"ref224","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/s0002-9610(00)00334-2","article-title":"Long-term results and multivariate analysis of prognostic factors in 138 consecutive patients operated on for Crohn's disease using \"bowel-sparing\" techniques","volume":"179","author":"Cristaldi","year":"2000","journal-title":"Am J Surg"},{"key":"ref225","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1111\/j.1365-2036.2004.02245.x","article-title":"Behaviour of the bowel wall during the first year after surgery is a strong predictor of symptomatic recurrence of Crohn's disease: a prospective study","volume":"20","author":"Parente","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"ref226","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jamcollsurg.2004.01.039","article-title":"A prospective, longitudinal study of nonconventional strictureplasty in Crohn's disease","volume":"199","author":"Sampietro","year":"2004","journal-title":"J Am Coll Surg"},{"key":"ref227","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1038\/ajg.2009.413","article-title":"CARD15 gene variants and risk of reoperation in Crohn's disease patients","volume":"104","author":"Maconi","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"ref228","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.cgh.2008.10.008","article-title":"Prospective study of long-term results and prognostic factors after conservative surgery for small bowel Crohn's disease","volume":"7","author":"Sampietro","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref229","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/0016-5085(90)90613-6","article-title":"Predictability of the postoperative course of Crohn's disease","volume":"99","author":"Rutgeerts","year":"1990","journal-title":"Gastroenterology"},{"key":"ref230","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/j.1572-0241.2001.03624.x","article-title":"Effect of ecabet sodium enema on mildly to moderately active ulcerative proctosigmoiditis: an open-label study","volume":"96","author":"Kono","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"ref231","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/SLA.0000000000003821","article-title":"Surgical prevention of anastomotic recurrence by excluding mesentery in Crohn's disease: the SuPREMe-CD study \u2013 A randomized clinical trial","volume":"272","author":"Luglio","year":"2020","journal-title":"Ann Surg"},{"key":"ref232","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.dld.2021.06.030","article-title":"Prevalence and significance of mesentery thickening and lymph nodes enlargement in Crohn's disease","volume":"54","author":"Sampietro","year":"2022","journal-title":"Dig Liver Dis"},{"key":"ref233","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.3390\/jcm11071961","article-title":"Has the removing of the mesentery during Ileo-colic resection an impact on post-operative complications and recurrence in Crohn's disease? Results from the resection of the mesentery study (remedy)","volume":"11","author":"Mineccia","year":"2022","journal-title":"J Clin Med"},{"key":"ref234","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1093\/ecco-jcc\/jjx187","article-title":"Inclusion of the mesentery in ileocolic resection for Crohn's disease is associated with reduced surgical recurrence","volume":"12","author":"Coffey","year":"2018","journal-title":"J Crohns Colitis"},{"key":"ref235","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1053\/j.gastro.2022.01.024","article-title":"Disease monitoring in inflammatory bowel disease: evolving principles and possibilities","volume":"162","author":"Plevris","year":"2022","journal-title":"Gastroenterology"},{"key":"ref236","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1053\/j.gastro.2019.10.034","article-title":"Development and validation of a test to monitor endoscopic activity in patients with Crohn's disease based on serum levels of proteins","volume":"158","author":"D'Haens","year":"2020","journal-title":"Gastroenterology"},{"key":"ref237","doi-asserted-by":"publisher","first-page":"1756284821999902","DOI":"10.1177\/1756284821999902","article-title":"Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients","volume":"14","author":"Facchin","year":"2021","journal-title":"Ther Adv Gastroenterol"},{"key":"ref238","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref239","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S2468-1253(21)00312-5","article-title":"Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis","volume":"6","author":"Singh","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref240","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1053\/j.gastro.2021.10.037","article-title":"Efficacy of biologic drugs in short-duration versus Long-duration inflammatory bowel disease: a systematic review and an individual-patient data meta-analysis of randomized controlled trials","volume":"162","author":"Ben-Horin","year":"2022","journal-title":"Gastroenterology"},{"key":"ref241","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/ecco-jcc\/jjw116","article-title":"Predicting outcomes to optimize disease Management in Inflammatory Bowel Diseases","volume":"10","author":"Torres","year":"2016","journal-title":"J Crohns Colitis"},{"key":"ref242","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/apt.13847","article-title":"Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis","volume":"45","author":"Mao","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"ref243","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S2468-1253(21)00014-5","article-title":"Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"6","author":"Barberio","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref244","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/1751-2980.12837","article-title":"Factors associated with disability in patients with ulcerative colitis: a cross-sectional study","volume":"21","author":"Marinelli","year":"2020","journal-title":"J Dig Dis"},{"key":"ref245","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1053\/j.gastro.2021.12.245","article-title":"How do we predict a Patient's disease course and whether they will respond to specific treatments?","volume":"162","author":"Verstockt","year":"2022","journal-title":"Gastroenterology"},{"key":"ref246","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1093\/ecco-jcc\/jjab050","article-title":"Scientific workshop steering committee. Results of the seventh scientific workshop of ECCO: precision medicine in IBD-disease outcome and response to therapy","volume":"15","author":"Verstockt","year":"2021","journal-title":"J Crohns Colitis"},{"key":"ref247","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Belgian inflammatory bowel disease research group; North-Holland gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial","volume":"371","author":"D'Haens","year":"2008","journal-title":"Lancet"},{"key":"ref248","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1093\/ibd\/izaa031","article-title":"Early vs late use of anti-TNFa therapy in adult patients with Crohn disease: a systematic review and meta-analysis","volume":"26","author":"Hamdeh","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"ref249","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.dld.2016.10.014","article-title":"Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the L\u00e9mann index","volume":"49","author":"Bodini","year":"2017","journal-title":"Dig Liver Dis"},{"key":"ref250","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/apt.15214","article-title":"Early combined immunosuppression may be effective and safe in older patients with Crohn's disease: post hoc analysis of REACT","volume":"49","author":"Singh","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"ref251","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1053\/j.gastro.2021.09.078","article-title":"Breaking through the therapeutic ceiling: what will it take?","volume":"162","author":"Raine","year":"2022","journal-title":"Gastroenterology"},{"key":"ref252","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2017","journal-title":"Lancet"},{"key":"ref253","doi-asserted-by":"publisher","first-page":"S001","DOI":"10.1093\/ecco-jcc\/jjab075.001","article-title":"OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in moderate-to-severe Crohn\u2019s disease: the SEAVUE study","volume":"15","author":"Irving","year":"2021","journal-title":"J Crohn's Colitis"},{"key":"ref254","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"ref255","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.1016\/j.cgh.2021.03.034","article-title":"Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and meta-analysis","volume":"20","author":"Ahmed","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref256","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1097\/MIB.0000000000000148","article-title":"Disappointing durable remission rates in complex Crohn's disease fistula","volume":"20","author":"Molendijk","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"ref257","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1093\/ecco-jcc\/jjaa226","article-title":"Ciclosporin or infliximab as rescue therapy in acute Glucorticosteroid-refractory ulcerative colitis: systematic review and network meta-analysis","volume":"15","author":"Barberio","year":"2021","journal-title":"J Crohns Colitis"},{"key":"ref258","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.cgh.2019.05.060","article-title":"PROTECT-GETAID study group. Efficacy of tumor necrosis factor antagonist treatment in patients with refractory ulcerative Proctitis","volume":"18","author":"Pineton de Chambrun","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref259","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1016\/j.cgh.2021.10.021","article-title":"Risk prediction and comparative efficacy of anti-TNF vs Thiopurines, for preventing postoperative recurrence in Crohn's disease: a pooled analysis of 6 trials","volume":"20","author":"Beelen","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref260","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1097\/MIB.0000000000001099","article-title":"Management of Inflammatory Bowel Disease in the elderly patient: challenges and opportunities","volume":"23","author":"Ananthakrishnan","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"ref261","doi-asserted-by":"publisher","first-page":"100070","DOI":"10.1016\/j.crphar.2021.100070","article-title":"Unmet needs in inflammatory bowel disease","volume":"2","author":"Rev\u00e9s","year":"2021","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"ref262","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nmeth.4642","article-title":"Statistics versus machine learning","volume":"15","author":"Bzdok","year":"2018","journal-title":"Nat Methods"},{"key":"ref263","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1053\/j.gastro.2019.08.058","article-title":"Application of artificial intelligence to gastroenterology and hepatology","volume":"158","author":"Le Berre","year":"2020","journal-title":"Gastroenterology"},{"key":"ref264","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1093\/ecco-jcc\/jjab169","article-title":"Application of artificial intelligence to clinical practice in inflammatory bowel disease \u2013 what the clinician needs to know","volume":"16","author":"Chen","year":"2022","journal-title":"J Crohns Colitis"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1031998\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T03:34:20Z","timestamp":1681184060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1031998\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,11]]},"references-count":264,"alternative-id":["10.3389\/fmed.2023.1031998"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1031998","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,11]]},"article-number":"1031998"}}